Somewhere in a brand-name drug company’s lifecycle management plan, there is usually a line item that reads something like: ‘Evaluate […]

The FDA Orange Book publishes patent expiry dates. Analysts read them, model them into revenue forecasts, and brief executives on

How to turn a single FDA regulatory date into a structured, repeatable, competitively timed sales funnel for active pharmaceutical ingredient

When a pharmaceutical brand launches an authorized generic, the press release typically says something about “patient access” or “expanding options.”

When a blockbuster drug loses patent protection, the resulting price war follows a predictable arc — but the speed, depth,

From Paragraph IV certifications to 30-month stays, Orange Book listings to authorized generics — a practitioner’s guide to the law

Pharmaceutical pipeline valuations collapse fastest not at clinical failure, but at patent expiry. The day a branded generic crosses the

What this article covers: How to read the FDA Orange Book like a competitive intelligence tool, not a regulatory checkbox.

Every drug company CFO knows the number. The day their new chemical entity (NCE) exclusivity expires is circled, starred, and